pharmaphorum
AUGUST 12, 2021
Health insurer Excellus BlueCross BlueShield has said it will not cover treatment with Biogen and Eisai’s new Alzheimer’s disease drug Aduhelm because it has not been shown to be medically effective. The post Health insurer Excellus will not fund Alzheimer’s drug Aduhelm appeared first on.
Digital Pharmacist
JULY 3, 2023
One effective way to mitigate these risks is by having comprehensive insurance coverage. Determining the coverage needs and evaluating insurance requirements for your pharmacy can ensure you’re adequately protected in the face of any unforeseen circumstances.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaTech
JUNE 10, 2025
It provides evidence-based recommendations on the use of vaccines for children and adults, informs decisions about insurance coverage, and helps determine eligibility for publicly funded programs such as Vaccines for Children (VFC). ACIP plays a foundational role in shaping immunization policy in the US. BIO President and CEO John F.
Pharmaceutical Technology
JUNE 6, 2025
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Commerce
JUNE 17, 2025
Artificial intelligence addresses key limitations of traditional health technology assessments—such as data gaps and time-intensive processes—through automation, real-time data integration, and advanced predictive modeling, leading to faster and more informed decisions. AI supports personalized medicine and real-world evidence integration.
pharmaphorum
SEPTEMBER 10, 2021
.” He blamed the poor performance on ” confusion, misinformation and controversy surrounding our data and the approval process.” “It is equally important to consider that the majority of patients with Alzheimer’s disease are likely to face higher risks of adverse events than the patients studied in the trials.”
pharmaphorum
OCTOBER 1, 2022
In this latest coverage, pharmaphorum speaks with Eugene Borukhovich. Borukhovich is hesitant to compare this year’s conference with the 2021 event. “I These events are great on stage, but also in understanding what’s coming next.”. What ignites his interest is the drive of the individuals to show up at the event.
Expert insights. Personalized for you.
98 
Let's personalize your content